الأحد 13 محرم 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| "A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlledClinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729)in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus" | MSD | Ongoing | Ertugliflozin | 3 | MK-8835-059-00 | King Salman Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Medical City (Riyadh) |
| Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer | SWOG (Southwest Oncology Group) | Ongoing | CARVEDILOL | 3 | S1501 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation | Acerta Pharma BV | Ongoing | Acalabrutinib | 3 | D8221C00001 | King Fahad Specialist Hospital (Dammam) |
| "A Phase III Double-blind Randomised Study Assessing the Efficacy andSafety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-lineTreatment for Patients with Histologically Confirmed, Locally Advanced(Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)" | AstraZeneca | Ongoing | Capivasertib | 3 | D3614C00001 | King Fahad Specialist Hospital (Dammam), King Abdullah Medical City (Makkah), Specialized Medical Center (Riyadh) |
| AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY | Roche | Terminated | Risdiplam | 2 | BN40703 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma | King Faisal Specialist Hospital & Research Center | Ongoing | Sorafenib (Nexavar) | 3 | RTOG 1112 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer | King Faisal Specialist Hospital & Research Center | Ongoing | DOCETAXEL, Paclitaxel, TAMOXIFEN and Letrozole | 3 | S1007 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease | Celgene | Ongoing | Ozanimod HCl | 3 | RPC01-3203 | King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer | NRG Oncology King Faisal Specialist Hospital & Research Center | Ongoing | CISPLATIN (CISPLATYL ) | 2 | NRG-HN002 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Study of Aflibercept in Uveitic Macular EDema (SAUD study) | King Khalid Eye Specialist Hospital | Rejected | Aflibercept | 3 | 18176/ | King Khaled Eye Specialist Hospital (Riyadh) |
تاريخ آخر تحديث: 08/05/2025 بتمام الساعة 03:17 مساء بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.